The development of novel biomarkers of doping is a key priority for anti-doping research. The challenges for the development and implementation of new biomarkers for anti-doping testing not only involve specific analytical approaches and omics technologies, but also require complementary expertise and research approaches that have been advanced in Quebec for the development of clinical biomarkers.


Applications eligible for this RFA should aim to develop:

  1. biomarkers of relevant prohibited substances or methods, or
  2. biomarkers of known confounding factors encountered in anti-doping testing.

For details, read the Request for Applications.